SpringerProtocols: Abstract: Molecular Simulations of Peptides: A Useful Tool for the Development of New Drugs and for the Study of Molecular Recognition

4. Molecular Simulations of Peptides: A Useful Tool for the Development of New Drugs and for the Study of Molecular Recognition

By: Massimiliano Meli³, Giorgio Colombo³

Abstract

Full Text

Download PDF (2392K)

The study of the molecular recognition and self-organization properties of peptides has emerged in recent years as a very active and diverse field of research, ranging from biomedicine to biotechnology and even to material sciences.

In the case of biomedicine, peptides can be used as ligands of biological receptors to gain insights into the structural, dynamical, and chemical determinants underlying the formation of complexes and identify new effectors of biological processes of interest. In the case of biotechnology and material science, short sequences have been used to understand the sequence determinants of the formation of ordered supra-molecular structures of nanoscale dimensions.

In this work, we will describe our research activities in these two areas of modern chemical biology. In the first part, we will describe the development of a new, specific, potent, and selective anticancer peptide and its use to obtain the information needed to identify a non-peptidic small molecular lead to be used as an inhibitor of cancer growth. In the second part, we will describe the introduction of a new method for the description of the self-organization process at the basis of the growth of ordered supra-molecular structures held together by weak, non-covalent, yet specific interactions.

Affiliation(s): (3) Istituto di Chimica del Riconoscimento Molecolare (ICRM) – C.N.R, Milano, Italy

Book Title: Peptide Microarrays: Methods and Protocols

Series: Methods in Molecular Biology | Volume: 570 | Pub. Date: Aug-01-2009 | Page Range: 77-153 | DOI: 10.1007/978-1-60327-394-7_4

Subject: Protein Science

Key Words: Drug design - peptides - self-organization - molecular recognition

References

Download References

1.	Eisenberg, D.; Nelson, R.; Sawaya, M. R.; Balbirnie, M.; Sambashivan, S.; Ivanova, M. I.; Madsen, A. Ø.; Riekel, C. (2006) The Structural Biology of Protein Aggregation Diseases: Fundamental Questions and Some Answers. Acc. Chem. Res 39, 568–575.

2.	Plescia, J.; Salz, W.; Xia, F.; Pennati, M.; Zaffaroni, N.; Daidone, M. G.; Meli, M.; Dohi, T.; Fortugno, P.; Nefedova, Y.; Gabrilovich, D. I.; Colombo, G.; Altieri, D. C. (2005) Rational design of Shepherdin, a novel anticancer agent. Cancer Cell 7, 457–467.

3.	Fortugno, P.; Beltrami, E.; Plescia, J.; Fontana, J.; Pradhan, D.; Marchisio, P. C.; Sessa, W. C.; Altieri, D. C. (2003) Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. USA 100, 13791–13796.

4.	Zaffaroni, N.; Daidone, M. G. (2002) Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Updat. 5, 65–72

5.	Verdecia, M. A., Huang, H., Dutil, E., Kaiser, D. A., Hunter, T., and Noel, J. P. (2000) Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct. Biol. 7, 602–608.

6.	Lindahl, E.; Hess, B.; van-der-Spoel, D. (2001) Gromacs 3.0: A package for molecular simulation and trajectory analysis. J. Mol. Mod. 7, 306–317.

7.	Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. (1998) Automated Docking Using a Lamarckian Genetic Algorithm and and Empirical Binding Free Energy Function. J. Comp. Chem. 19, 1639–1662.

8.	Gyurkocza, B.; Plescia, J.; Raskett, G. M.; Garlick, D. S.; Lowry, P. A.; Carter, B. Z.; Andreeff, M.; Meli, M.; Colombo, G.; Altieri, D. C. (2006) Antileukemic activity of Shepherdin and molecular diversity of hsp90 inhibitors. J. Natl. Cancer Inst. 98, 1068–1077.

9.	Meli, M.; Pennati, M.; Curto, M.; Daidone, M. G.; Plescia, J.; Toba, S.; Altieri, D. C.; N., Z.; Colombo, G. (2006) Small-Molecule targeting of HSP90 chaperone function: rational identification of a new anti-cancer lead. J. Med. Chem. 49, 7721–30.

10.	Accounts of Chemical Research (2006) 39, Special issue on aggregation.

11.	de-la-Paz, M. L.; de-Mori, G. M. S.; Serrano, L.; Colombo, G. (2005) Sequence dependence of amyloid fibril formation: Insights from molecular dynamics simulations. J. Mol. Biol. 349, 583–596.

12.	De Mori, G. M. S.; Micheletti, C.; Colombo, G. (2004) All-atom folding simulations of the villin headpiece from stochastically selected coarse-grained structures. J. Phys. Chem. B 108, 12267–12270.

13.	Meli, M.; Morra, G.; Colombo, G. (2008) Investigating the mechanism of peptide aggregation: insights from mixed monte carlo-molecular dynamics simulations. Biophys. J. 94, 4414–26.

14.	Daura, X.; Gademann, K.; Jaun, B.; Seebach, D.; Gunsteren, W. F. v.; Mark, A. E. (1999) Peptide folding: when simulation meets experiment. Angew. Chemie Intl. Ed. 38, 236–240.

15.	Kabsch, W.; Sander, C. (1983) Dictionary of Protein Secondary Structure: Pattern Recognition of Hydrogen-Bonded and Geometrical Features. Biopolymers 22, 2576–2637.

16.	van Gunsteren, W. F.; Daura, X.; Mark, A. E. (1998) GROMOS Force Field. Encyclopedia Comput. Chem. 2, 1211–1216.

17.	van Gunsteren, W. F.; Billeter, S. R.; Eising, A. A.; Hunenberger, P. H.; Kruger, P.; Mark, A. E.; Scott, W. R. P.; Tironi, I. G. (1996) Biomolecular Simulation: The GROMOS96 Manual and User Guide. In vdf Hochschulverlag, ETH Zurich: Switzerland..

18.	Darden, T.; York, D.; Pedersen, L. (1993) Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089–10092.

19.	Essmann, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. (1995) A smooth particle mesh Ewald potential. J. Chem. Phys.103, 8577–8592.

20.	Unger, R.; Moult, J. (1993) Genetic algorithm for protein folding simulation. J. Mol. Biol. 231, 75–81.

21.	Rensburg, E. J. v.; Orlandini, E.; Whittington, S. (1996) Monte-Carlo study of the interacting self-avoiding walk in three dimension. J. Stat. Phys.82, 155–181.

22.	Lee, J.; Scheraga, H.; Rackovsky, S. (1997) New optimization method for conformational energy calculations on polypeptides: conformational space annealing. J. Comput. Chem. 18, 1222–1232.

23.	Irbäck, A.; Potthast, F. (1995) Studies of an off-lattice model for protein folding: sequence dependence and improved sampling at finite temperature. J. Chem. Phys.103, 10298–10305.

24.	Hansmann, U.; Okamoto, Y. (1999) New Monte Carlo algorithms for protein folding. Curr. Opin. Struct. Biol. 9, 177–183.

25.	Scheraga, H.; Hao, M. (1999) Entropy sampling Monte Carlo for polypeptides and proteins. Adv. Chem. Phys. 105, 243–272.

26.	Arkin, H.; Yarkin, F.; Celik, T.; Berg, B.; Meirovitch, H. (2002) Multicanonical simulations of some peptides. Comp. Phys. Comm. 147, 600–603.

27.	Garcia, A.; Onuchic, J. (2003) Folding a protein in a computer: an atomic description of the folding/unfolding of protein. Proc Natl Acad Sci USA 100, 13898–13903.

28.	Kolinski, A.; Godzik, A.; Skolnick, J. (1998) Monte Carlo studies of the thermodynamics and kinetics of reduced protein models: Application to small helical, b, and a, b proteins. J. Chem. Phys. 108, 2608–2617.

29.	Micheletti, C.; Banavar, J. R.; Maritan, A.; Seno, F. (1999) Protein structures and optimal folding from a geometrical variational principle. Phys. Rev. Lett. 82, 3372–3375.

30.	Baker, D. (2000) A surprising simplicity to protein folding. Nature 405, 39–42.

31.	Clementi, C.; Nymeyer, H.; Onuchic, J. N. (2000) Topological and energetic factors: what determines the structural details of the transition state ensemble and en-route intermediates for protein folding? An investigation for small globular proteins. J. Mol. Biol. 298, 937–953.

32.	Klimov, D. K.; Thirumalai, D. (2000) Native topology determines force-induced unfolding pathways in globular proteins. J. Chem. Phys. 113, 8319–8328.

33.	Cieplak, M.; Hoang, T. X. (2000) Scaling of folding properties in go models of proteins. J. Biol. Phys. 26, 273–294.

34.	Hao, H. M.; Scheraga, H. A. (1997) On foldable protein-like models: a statistical-mechanical study with Monte Carlo simulations. Physica A 244, 124–145.

35.	Tiana, G.; Broglia, R. A. (2001) Statistical Analysis of Native Contact Formation in the Folding of Designed Model Proteins. J. Chem. Phys. 114, 2503.

36.	Lazaridis, T.; Karplus, M. (1997) New view of protein folding reconciled with the old through multiple unfolding trajectories. Science 278, 1928–1931.

37.	Bahar, I.; Erman, B.; Jernigan, R. L.; Atilgan, A. R.; Covell, D. G. (1999) Collective Motions in HIV-1 Reverse Transcriptase: Examination of Flexibility and Enzyme Function. J. Mol. Biol. 285, 1023–1037.

38.	Hoang, T. X.; Cieplak, M. (2000) Molecular dynamics of folding of secondary structures in go-type models of proteins. J. Chem. Phys. 112, 6851–6862.

39.	Favrin, G.; Irback, A.; Wallin, S. (2002) Folding of a small helical protein using hydrogen bonds and hydrophobicity forces. Proteins 47, 99–105.

40.	Vieth, M.; Kolinski, A.; Brooks, C.; Skolnick, J. (1994) Prediction of the folding pathways and structure of the gcn4 leucine zipper. J. Mol. Biol. 237, 361–367.

41.	Liwo, A.; Pincus, M.; Wawak, R.; Rackowsky, S.; Scheraga, H. (1993) Prediction of protein conformation on the basis of a search for compact structures; test on avian pancreatic polypeptide. Protein Sci. 2, 1715–1731.

42.	Park, B.; Levitt, M. (1996) Energy functions that discriminate x-ray and near-native folds from well-constructed decoys. Proteins 258, 367–392.

43.	Kolinski, A.; Galazka, W.; Skolnick, J. (1993) A general method for the prediction of the three dimensional structure and folding pathway of globular proteins: Application to designed helical proteins. J. Chem. Phys. 98(9), 7420–7433.

44.	Kolinsky, A.; Skolnick, J. (1994) Monte Carlo simulations of protein folding. I. Lattice model and interaction scheme. Proteins 18, 338–352.

45.	Correa, P. (1990) The building of protein structures from a-carbon coordinates. Proteins 7, 366–377.

46.	Rey, A.; Skolnick, J. (1991) Efficient algorithm for the reconstruction of a protein backbone from the a-carbon coordinates. J. Comput. Chem. 13, 443–456.

47.	Holm, L.; Sander, C. (1991) Database algorithm for generating protein backbone and side-chain coordinates from a c trace, application to model building and detection of coordinate errors. J. Mol. Biol. 218, 183–194.

48.	Bower, M.; Cohen, F.; Dunbrak, R. (1997) Prediction of protein side-chain rotamers from a backbone-dependent rotamer library. J. Mol. Biol. 267, 1268–1282.

49.	Kazmierkiewicz, R.; Liwo, A.; Scheraga, H. (2003) Addition of side chains to a known backbone with defined side-chain centroids. Biophys. Chem. 100, 261–280.

50.	Kabsch, W. (1978) A discussion of the solution for the best rotation to relate two sets of vectors. Acta Crystallogr. A, 34, 828–829.

51.	de-Mori, G. M. S.; Colombo, G.; Micheletti, C. (2005) Study of the villin headpiece folding dynamics by combining coarse-grained Monte Carlo evolution and all-atom molecular dynamics. Proteins-struct. funct. bioinform. 58, 459 471.

52.	Hobohm, U.; Scharf, M.; Schneider, R.; Sander, C. (1992) Selection of a representative set of structures from the brookhaven protein data bank. Protein Sci. 1, 409–417.

53.	Hobohm, U.; Sander, C. (1992) Enlarged representative set of protein structures. Protein Sci. 2, 522.

54.	Hengartner, M. O. (2000) The biochemistry of apoptosis. Nature 107, 770–776.

55.	Whitesell, L.; Lindquist, S. (2005) Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761–772.

56.	Takayama, S.; Reed, J. C.; Homma, S. (2003) Heat-shock proteins as regulators of apoptosis. Oncogene 22, 9041–9047.

57.	Dymock, B. W.; Drysdale, M. J.; McDonald, E.; Workman, P. (2004) Inhibitors of HSP90 and other chaperones for the treatment of cancer. Expert. Opin. Ther. Patents 14, 837–847.

58.	Morimoto, R. I.; Santoro, M. G. (1998) Stress-inducible responses and heat shock proteins: new pharmacologic targets for cytoprotection. Nat. Biotechnol. 16, 833–838.

59.	Whitesell, L.; Lindquist, S. (2005) Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761–772.

60.	Young, J. C.; Moarefi, I.; Hartl, F. U. (2001) Hsp90: A specialized but essential protein-folding tool. J. Cell. Biol. 154, 267–273.

61.	Morishima, Y.; Murphy, P. J.; Li, D. P.; Sanchez, E. R.; Pratt, W. B. (2000) Stepwise assembly of a glucocorticoid receptor hsp90 heterocomplex resolves two sequential ATP-dependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket. J. Biol. Chem. 275, 18054–18060.

62.	Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. (2000) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 275, 37181–37186.

63.	Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; Di Nola, A.; Haak, J. R. (1984) Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684.

64.	Berendsen, H. J. C.; Grigera, J. R.; Straatsma, T. P. (1987) The missing term in effective pair potentials. J. Phys. Chem. 91, 6269–6271.

65.	Hess, B.; Bekker, H.; Fraaije, J. G. E. M.; Berendsen, H. J. C. (1997) A linear constraint solver for molecular simulations. J. Comp. Chem. 18, 1463–1472.

66.	Miyamoto, S.; Kollman, P. A. (1992) SETTLE: An analytical version of the SHAKE and RATTLE algorithms for rigid water models. J. Comp. Chem. 13, 952–962.

67.	Spoel, D. v. d.; Lindahl, E.; Hess, B.; Buuren, A. R. v.; Apol, E.; Meulenhoff, P. J.; Tieleman, D. P.; Sijbers, A. L. T. M.; Feenstra, K. A.; Drunen, R. v.; Berendsen, H. J. C. (2004) Gromacs User Manual version 3.2. www.gromacs.org.

68.	Daura, X.; Antes, I.; van Gunsteren, W. F.; Thiel, W.; Mark, A. E. (1999) The effect of motional averaging on the calculation of NMR-derived structural properties. Proteins: Struct. Funct. Genet. 36, 542–555.

69.	Guex, N.; Peitsch, M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 18, 2714–2723.

70.	Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F. U.; Pavletich, N. P. (1997) Crystal Structure of Hsp90–Geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 89, 239–250.

71.	Solmajer, T.; Mehler, E. L. (1991) Electrostatic Screening in Molecular Dynamics simulations. Protein Eng. 4, 911.

72.	Hetenyi, C.; van der Spoel, D. (2002) Efficient docking of peptides to proteins without prior knowledge of the binding site. Prot. Sci. 11, 1729–1737.

73.	Lee, Y. S.; Marcu, M. G.; Neckers, L. (2004) Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans–cis isomerization of geldanamycin. Chem. Biol. 11, 991–998.

74.	Roe, S. M.; Ali, M. M.; Meyer, P.; Vaughan, C. K.; Panaretou, B.; Piper, P. W.; Prodromou, C.; Pearl, L. H. (2004) The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 116, 87–98.

75.	Altieri, D. C. (2003) Validating Survivin as a Cancer Therapeutic Target. Nat. Rev. Cancer 3, 46–54.

76.	Isaacs, J. S.; Xu, W.; Neckers, L. (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3, 213–217.

77.	Neckers, L.; Ivy, S. P. (2003) Heat Shock Protein 90. Curr. Op. Oncol. 15, 419–424.

78.	Chen, Y. N.; Sharma, S. K.; Ramsey, T. M.; Jiang, L.; Martin, M. S.; Baker, K.; P. D. Adams; Bair, K. W. (1999) Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. USA 96, 4325–4329.

79.	Sawada, M.; Hayes, P.; Matsuyama, S. (2003) Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat. Cell Biol. 5, 352–357.

80.	Swanton, C. (2004) Cell-cycle targeted therapies. Lancet Oncol. 5, 27–36.

81.	Vogelstein, B.; Lane, D.; Levine, A. J. (2000) Surfing the p53 network. Nature 408, 307–310.

82.	Johnstone, R. W.; Ruefli, A. A.; Lowe, S. W. (2002) Apoptosis: A link between cancer genetics and chemotherapy. Cell 108, 153–164.

83.	Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848.

84.	Sausville, E. A.; Tomaszewski, J. E.; Ivy, P. (2003) Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets 3, 377–383.

85.	Beere, H. M. (2004) “The stress of dying”: The role of heat shock proteins in the regulation of apoptosis. J. Cell Sci. 117, 2641–2651.

86.	Kamal, A.; Boehm, M. F.; Borrows, F. J. (2004) Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 10, 283–290

87.	Guillemard, V.; Saragovi, H. U. (2004) Novel approaches for targeted cancer therapy. Curr. Cancer Drug Targets 4, 313–326.

88.	Muchmore, S. W.; Chen, J.; Jakob, C.; Zakula, D.; Matayoshi, E. D.; Wu, W.; Zhang, H.; Li, F.; Ng, S. C.; Altieri, D. C. (2000) Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol. Cell 6, 173–182.

89.	Li, A.; Daggett, V. (1998) Molecular Dynamics Simulation of the Unfolding of Barnase: Characterization of the Major Intermediate. J. Mol. Biol. 275, 677–694.

90.	Vogelstein, B.; Kinzler, K. W. (2004) Cancer genes and the pathways they control. Nat. Med. 10, 789–799.

91.	O'Dwyer, M. E.; Druker, B. J. (2000) Status of Bcr-Abl tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr. Op. Oncol. 12, 594–597.

92.	O'Dwyer, M. E.; Druker, B. J. (2000) STI571: An inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukemia. Lancet Oncol. 1, 207–211.

93.	Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304, 1497–1500.

94.	Workman, P. (2003) Overview: Translating Hsp90 Biology into Hsp90 Drugs. Curr. Cancer. Drug. Targets 3, 297–300.

95.	Mehler, E. L.; Solmajer, T. (1991) Electrostatic effects in proteins. Comparison of dielectric and charge models. Prot. Eng. 4, 903–910.

96.	Daura, X.; Jaun, B.; Seebach, D.; van Gunsteren, W. F. v.; Mark, A. E. (1998) Reversible Peptide Folding in Solution by Molecular Dynamics Simulation. J. Mol. Biol. 280, 925–932.

97.	Catalyst (2005) Accelrys, San Diego CA, USA.

98.	Ferris, J. P.; Devadas, B.; Huang, C. H.; Ren, W. Y. (1985) Nucleosides from carbohydrate adducts of diaminomaleonitrile. A novel synchapter of 5-amino-1-(beta-D-ribofuranosyl)imidazole-4-carboxamide and 5-amino-1-(beta-D-ribopyranosyl)imidazole-4-carboxamide. J. Org. Chem. 50, 747–754.

99.	Folini, M.; Brambilla, C.; Villa, R.; Gandellini, P.; Vignati, S.; Paduano, F.; Daidone, M. G.; Zaffaroni, N. (2005) Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells Eur. J. Cancer 41, 624–634

100.	Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen, N.; Spampinato, C.; Modrich, P.; Chiosis, G. (2004) Targeting wide-range oncogenic transformation via PU24FCL, a specific inhibitor of Tumor Hsp90. Chem. Biol. 11, 787–797.

101.	Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. (2002) Development of a purine-scaffold novel class of Hsp90 Binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 10, 3555–3564.

102.	Dymock, B. W.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Massey, A.; McDonald, E.; Hubbard, R. E.; Surgenor, A.; Roughley, S. D.; Webb, P.; Workman, P.; Wright, L.; Drysdale, M. J. (2005) Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 48, 4212–4215.

103.	Wright, L.; Barril, X.; Dymock, B. W.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M. J.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. (2004) Structure–Activity relationships in purine-based inhibitor binding to Hsp90 Isoforms. Chem. Biol. 11, 775–785.

104.	Holt, S. E.; Aisner, D. L.; Baur, J.; Tesmer, V. M.; Dy, M.; Ouellette, M.; Trager, J. B.; Morin, G. B.; Toft, D. O.; Shay, J. W.; Wright, W. E.; White, M. A. (1999) Functional requirement of p23 and Hsp90 in telomerase complexes Genes & Devel. 13, 817–826.

105.	Janin, Y. L. (2005) Heat Shock Protein 90 inhibitors. A text book example of medicinal chemistry? J. Med. Chem. 48, 7503–7512.

106.	Sausville, E. A. (2004) Geldanamycin Analogs. J. Chemother. 16(S4), 68–69.

107.	Giri, S.; Nath, N.; Smith, B.; Viollet, B.; Singh, A. K.; Singh, I. (2004) 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: A possible role of AMP-activated protein kinase. J. Neurosci. 24, 479–487.

108.	Nath, N.; Giri, S.; Prasad, R.; Salem, M. L.; Singh, A. K.; Singh, I., (2005) 5-Aminoimidazole-4-carboxamide ribonucleoside: A novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis J. Immunol. 175, 566–574.

109.	Rattan, R.; Giri, S.; Singh, A. K.; Singh, I. (2005) 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated Protein Kinase. J. Biol. Chem. 280, 39582–39593.

110.	Paduano, F.; Villa, R.; Pennati, M.; Folini, M.; Binda, M.; Daidone, M. G.; Zaffaroni, N. (2006) Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol. Cancer Ther. 5, 179–186.

111.	Rutledge, G.; Behnke, E.; Liang, Y. X.; You, S. W.; Tay, D. K. C.; Zhang, S.; So, K. F.; Schneider, G. E. (2006) Nano neuro knitting: Peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision. PNAS 103, 5054–5059.

112.	Daidone, I.; Amadei, A.; Di Nola, A. (2005) Thermodynamic and kinetic characterization of a ß-hairpin peptide in solution: an extended phase space sampling by molecular dynamics simulations in explicit water. Proteins 59, 510–518.

113.	Ma, B.; Nussinov, R. (2002) Molecular dynamics simulation of alanine beta-sheet oligomers: insight into amyloid formation. Protein Sci. 11, 2335–2350.

114.	Urbanc, B.; Ding, C. L.; Sammond, D.; Khare, S. (2004) Molecular dynamics simulation of amyloid beta dimer formation. Biophys. J. 87, 2310.

115.	Dokholyan, N. V. (2006) Studies of folding and misfolding using simplified models. Curr. Opin. Struct. Biol.16, 79–85.

116.	Flock, D.; Daidone, I.; Di Nola, A. (2004) A Molecular Dynamics study of acylphosphatase in aggregation promoting conditions: the influence of TFE/water solvent. Biopolymers 75, 491–496.

117.	Wei, G.; Shea, J. E. (2006) Effects of solvent on the structure of the Alzheimer amyloid-beta(25-35) peptide. 91, 1638–1647.

118.	Cuniasse, P.; Raynal, I.; Yiotakis, A.; Dive, V. (1997) Accounting for Conformational Variability in NMR Structure of Cyclopeptides: Ensemble Averaging of Interproton Distance and Coupling Constant Restraints. J. Am. Chem. Soc. 19, 5239–5248.

119.	Favrin, G.; Irbäck, A.; Mohanty, S. (2004) Oligomerization of Amyloid Aß16–22 Peptides Using Hydrogen Bonds and Hydrophobicity Forces. Biophys. J.87, 3657–3664.

120.	Burkoth, T. S.; Benzinger, T. L. S.; Jones, D. N. M.; Hallenga, K.; Meredith, S. C.; Lynn, D. G. (1998) C-Terminal PEG Blocks the Irreversible Step in –Amyloid(10-35) Fibrillogenesis. J. Am. Chem. Soc. 120, 7655–7656.

121.	Burkoth, T. S.; Benzinger, T. L. S.; Urban, V.; Lynn, D. G.; Meredith, S. C.; Thiyagarajan, P. (1999) Self-Assembly of A(10-35)-PEG Block Copolymer Fibrils. J. Am. Chem. Soc. 121, 7429–7430.

122.	Zheng, J.; Tsai, M. B.; Nussinov, R. (2006) Structural stability and dynamics of an amyloid-forming peptide GNNQQNY from the yeast prion sup-35. Biophys. J. 91, 824–833.

123.	Walsh, D. M.; Klyubin, I.; Fadeeva, J. V.; Cullen, W. K.; Anwyl, R.; Wolfe, M. S.; Rowan, R. J.; Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539.

124.	Bucciantini, M.; Giannoni, E.; Chiti, F.; Baroni, F.; Formigli, L.; Zurdo, J.; Taddei, N.; Ramponi, G.; Dobson, C. M.; Stefani, M. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507–511.

125.	Kayed, R.; Head, E.; Thompson, J. L.; McIntire, T. M.; Milton, S. C.; Cotman, C. W.; Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486–489.

126.	Mousseau, N.; Derreumaux, P. (2005) Exploring the Early Steps of Amyloid Peptide Aggregation by Computers. Acc. Chem. Res. 38, 885–891.

127.	Nilsson, M. R. (2004) Techniques to study amyloid fibril formation in vitro. Methods 34, 151–160.

128.	Bitan, G.; Teplow, D. B. (2004) Rapid photochemical cross-linking-a new tool for studies of metastable, amyloidogenic protein assemblies. Acc. Chem. Res. 37, 357–364.

129.	Nelson, R.; Sawaya, M. R.; Balbirnie, M.; Madsen, A. O.; Riekel, C.; Grothe, R.; Eisenberg, D. (2005) Structure of the cross-β spine of amyloid-like fibrils. Nature 435, 773–778.

130.	Fersht, A. R. (2002) On the simulation of protein folding by short time scale molecular dynamics and distributed computing. PNAS 99, 14122–14125.

131.	Derrick, J. P.; Wigley, D. B. (1992) Crystal-structure of a streptococal protein-G domain bound to an fab fragment. Nature 359, 752–754.

132.	Gabius, H.-J. (1998) The How and Why of Protein–carbohydrate Interaction: a Primer to Theoretical Concept and a Guide to application in drug Design. Pharmaceutical Res. 15, 23–30.

133.	Ban, T.; Yamaguchi, K.; Goto, Y. (2006) Direct Observation of Amyloid Fibril Growth, Propagation, and Adaptation. Acc. Chem. Res. 39, 663–670.

134.	Patino, M. M.; Liu, J. J.; Glover, J. R.; Lindquist, S. (1996) Support for the prion hypochapter for inheritance of a phenotypic trait in yeast. Science 273, 622–626.

135.	Serio, T. R. (2000) Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289, 1317–1321.

Comments (Loading...)

Post comment/View all comments